MTOR and gastric cancer: The published data support that use of mTOR inhibitors against oesophageal cancer (everolimus, NCT00985192 by translational oncology research international, USA in 2009) [165], gastric cancer (everolimus, NCT00519324 by Novartis pharmaceuticals in 2009) [166], everolimus plus cisplatin, NCT00632268 by National Taiwan University Hospital in 2008 [167], hepatocellular carcinoma, pancreatic cancer, and colorectal cancer, where a number of mTOR inhibitors have been tested and found safe and effective against the disease.